Hamilton, Ontario, November 16, 2018 – The Centre for Probe Development and Commercialization (CPDC) is proud to introduce the new Head of Business Development, Bruno Paquin, PhD.
Bruno comes to us with years of experience in research and development and he brings with him extensive knowledge of scientific operations in life and health sciences, as well as an impressive resume of business development expertise.
“This is a very exciting addition to the CPDC team,” stated Dr. Joe McCann, CEO of CPDC. “Bruno will lead the growth of our radiopharmaceutical imaging products business as well as provide business support to our contract services unit that is focused on regulatory affairs and clinical trial management. With Bruno’s knowledge and expertise, he will play a key role in keeping CPDC at the forefront of the industry.”
Bruno received his PhD in Biochemistry from Université de Montréal before conducting his post-doctoral research at the University of Albany. He became the Laboratory Director at Université de Montréal, Département de Biochimie, where he was responsible for the management and direction of a team of scientists. In 2000, he became the head of the Technology Development Unit at Genizon Biosciences Inc., where he was appointed the Executive Director, Head of Business Development.
In 2010, Bruno became a consultant for Business & Strategy Development in Life Sciences, Genetics and Pharmacogenomics for several organizations, and then went on to become VP of Business Development for Immuni T in Montréal in 2011. He has published extensively, is a named inventor in over 24 patent applications and has presented at international conferences.
Dr. Paquin stated, “I’m proud to become part of such an impressive organization that plays a major role in helping Canadians. I look forward to working alongside Dr. McCann and the rest of the team to extend the reach of CPDC products and services.”
The Centre for Probe Development and Commercialization (CPDC) is a Centre of Excellence for Commercialization and Research (CECR) located at McMaster University in Hamilton, Ontario, Canada. CPDC is a private, not-for-profit company and global leader in the discovery, development and commercialization of next-generation radiopharmaceuticals that was created with the support of multiple stakeholders, including the Networks of Centres of Excellence (NCE), McMaster University and The Ontario Institute for Cancer Research (OICR). Since its foundation in 2008, CPDC has established a pipeline of products along with a robust and reliable global supply of innovative diagnostic and therapeutic radiopharmaceuticals used daily for the detection and treatment of human diseases such as cancer. For more information about CPDC, please visit: www.imagingprobes.ca.
Centre for Probe Development and Commercialization
Angela Laurentani, 905 525-9140, ext. 21212
The Centre for Probe Development and Commercialization (CPDC) and adMare BioInnovations (adMare) are pleased to announce they have formed a new collaboration, “The CPDC-adMare Radiopharmaceutical Initiative (CARI)” to bring their respective resources together to advance an area of tremendous therapeutic and commercial potential in which Canada can gain a considerable global competitive advantage: radiopharmaceuticals. This
Hamilton, Ontario, September 8, 2020 – Isotopia Molecular Imaging and CPDC are pleased to announce that they have entered into an agreement for the production and distribution of no-carrier-added Lutetium-177 (n.c.a. Lu-177), a critical medical radioisotope used in the manufacturing of radiopharmaceuticals for treatment of many types of cancer, including neuroendocrine tumors and prostate cancer.
Hamilton, Ontario June 23, 2020 The Centre for Probe Development and Commercialization (CPDC) announced that its Board of Directors has appointed Justyna Kelly as Chief Executive Officer (CEO). The CEO appointment has taken effect on June 18, 2020. Justyna Kelly was appointed the role of interim CEO in December 2019. Mark Lundie, outgoing Chair of